Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Exelixis
Klus Pharma Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc